Epoxyeicosatrienoic acid

Chemical structure of 14,15-epoxyeicosatrienoic acid

The epoxyeicosatrienoic acids or EETs are signaling molecules formed within various types of cells by the metabolism of arachidonic acid by a specific subset of cytochrome P450 enzymes, termed cytochrome P450 epoxygenases.[1] They are nonclassic eicosanoids.

EETs are generally short-lived, being rapidly converted from epoxides to less active or inactive dihydroxy-eicosatrienoic acids (diHETrEs) by a widely distributed cellular enzyme, soluble epoxide hydrolase (sEH), also termed epoxide hydrolase 2. The EETs consequently function as transiently acting, short-range hormones; that is, they work locally to regulate the function of the cells that produce them (i.e. they are autocrine agents) or of nearby cells (i.e. they are paracrine agents). The EETs have been most studied in animal models where they show the ability to lower blood pressure possibly by a) stimulating arterial vasorelaxation and b) inhibiting the kidney's retention of salts and water to decrease intravascular blood volume. In these models, EETs prevent arterial occlusive diseases such as heart attacks and brain strokes not only by their anti-hypertension action but possibly also by their anti-inflammatory effects on blood vessels, their inhibition of platelet activation and thereby blood clotting, and/or their promotion of pro-fibrinolytic removal of blood clots.[2] With respect to their effects on the heart, the EETs are often termed cardio-protective. Beyond these cardiovascular actions that may prevent various cardiovascular diseases, studies have implicated the EETs in the pathological growth of certain types of cancer and in the physiological and possibly pathological perception of neuropathic pain. While studies to date imply that the EETs, EET-forming epoxygenases, and EET-inactivating sEH can be manipulated to control a wide range of human diseases, clinical studies have yet to prove this. Determination of the role of the EETS in human diseases is made particularly difficult because of the large number of EET-forming epoxygenases, large number of epoxygenase substrates other than arachidonic acid, and the large number of activities, some of which may be pathological or injurious, that the EETs possess.[3]

  1. ^ Boron WF (2003). Medical Physiology: A Cellular And Molecular Approach. Elsevier/Saunders. p. 108. ISBN 1-4160-2328-3.
  2. ^ Spector AA, Fang X, Snyder GD, Weintraub NL (Jan 2004). "Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function". Progress in Lipid Research. 43 (1): 55–90. doi:10.1016/S0163-7827(03)00049-3. PMID 14636671.
  3. ^ Tacconelli S, Patrignani P (2014). "Inside epoxyeicosatrienoic acids and cardiovascular disease". Frontiers in Pharmacology. 5: 239. doi:10.3389/fphar.2014.00239. PMC 4226225. PMID 25426071.

Epoxyeicosatrienoic acid

Dodaje.pl - Ogłoszenia lokalne